PMDA drug package insert
エリスロシン錠100mg
PMDA Prescription drug · ヴィアトリス・ヘルスケア合同会社 · package insert Jul 8, 2026
Key facts
| Brand names | エリスロシン錠100mg, エリスロシン錠200mg |
|---|---|
| Nonproprietary names | エリスロマイシンステアリン酸塩 |
| Companies | 製造販売元／ヴィアトリス・ヘルスケア合同会社, 販売元／ヴィアトリス製薬合同会社 |
| Product type | Prescription drug |
| Therapeutic category | マクロライド系抗生物質製剤 |
| Therapeutic category codes | 876141 |
| YJ codes | 6141004F1038, 6141004F2042 |
| Approval numbers | 21500AMZ00087, 21500AMZ00088 |
| Package insert edition | 第5版 |
| Package insert date | Jul 8, 2026 |
| PMDA document key | 730869_6141004F1038_3 |
| PMDA company code | 730869 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: